Published in
Elsevier, Clinical Colorectal Cancer, 4(20), p. 318-325, 2021
DOI: 10.1016/j.clcc.2021.07.003
Links
Tools
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
Journal article published in 2021 by
Alessandro Parisi 
,
Giampiero Porzio,
Katia Cannita,
Olga Venditti,
Antonio Avallone ,
Roberto Filippi,
Lisa Salvatore ,
Giampaolo Tortora,
Marta Ribelli,
Olga Nigro,
Fabio Gelsomino ,
Andrea Spallanzani ,
Valeria Zurlo,
Silvana Leo,
Emanuela Dell'Aquila
and other authors.
,
Giampiero Porzio,
Katia Cannita,
Olga Venditti,
Antonio Avallone ,
Roberto Filippi,
Lisa Salvatore ,
Giampaolo Tortora,
Marta Ribelli,
Olga Nigro,
Fabio Gelsomino ,
Andrea Spallanzani ,
Valeria Zurlo,
Silvana Leo,
Emanuela Dell'Aquila
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 